The pharmacokinetics of vancomycin were studied in four patients on continuous ambulatory peritoneal dialysis. After a single intravenous infusion of 10 mg/kg of total body weight, multiple blood, urine, and dialysate samples were collected during a 72-h evaluation period. The steady-state volume of distribution was 0.73 ± 0.07 (mean ± standard deviation) liters/kg with a beta half-life of 90.2 ± 24.2 h. The continuous ambulatory peritoneal dialysis clearance of vancomycin was 1.35 ± 0.35 ml/min, and the serum clearance was 6.4 ± 1.1 ml/min. Peritoneal dialysate concentrations of vancomycin were rapidly attained after the intravenous infusion and averaged 2.2 ± 0.7 mg/liter throughout the 72-h observation period. A loading dose of 23 mg/kg followed by a maintenance dose of 17 mg/kg every 7 days should attain and maintain therapeutic serum and dialysate concentrations. More frequent dosing may be necessary for less susceptible organisms.
Continuous ambulatory peritoneal dialysis (CAPD) is a self-dialysis procedure which is now widely used for the management of end-stage renal disease. The most frequent complication of CAPD is peritonitis. Over 65% of these infections are caused by gram-positive organisms, and ca. 50% are due to staphylococcal species (P. K. Peterson, and W. F. Keane, in J. S. Remington and M. N. Swartz, ed., Current Clinical Topics in Infectious Diseases, in press). Clinical effectiveness of vancomycin against staphylococci is well documented (1, 5, 7, 9, 14) . The MICs of vancomycin have ranged from 0.63 to 3.12 mg/liter for Staphylococcus aureus and from 1.56 to 3.12 mg/liter for Staphylococcus epidermidis (6, 8, 10, 16) . Thus, vancomycin could be an extremely useful antibiotic for the management of infections in the CAPD patient.
The pharmacokinetics of intravenously administered vancomycin in patients undergoing CAPD have, until recently, not been rigorously evaluated (4) . The purpose of this study was to assess vancomycin concentrations in serum, periotoneal dialysate fluid, and urine after administration of a single intravenous dose. The pharmacokinetic parameters determined are as follows: elimination rate, elimination halflife, volume of distribution, total body clearance, and peritoneal clearance.
MATERIALS AND METHODS Patients. Four patients (two males and two females) with end-stage renal disease undergoing CAPD gave written, informed consent to participate in this study. All patients had been on CAPD for at least 2 months (range, 2 to 14 months), and none had experienced peritonitis in the previous 2 months. Patients requiring systemic antibiotic therapy or who had a known allergy to vancomycin were excluded. Each patient had a physical examination and a laboratory screening profile done before and after they were studied.
All patients had an indwelling Tenckhoff catheter in place. The CAPD exchange schedule for all patients was 2 liters of * Corresponding author.
2.5% glucose peritoneal dialysis solution (PD I; Travenol Laboratories, Deerfield, Ill.) four times a day. An intravenous catheter was placed in a forearm vein and was used to infuse the drug. A single dose of 10 mg/kg of total body weight was infused over a 30-min period. A heparin lock was placed in a forearm vein in the contralateral arm, and blood samples were collected before and 0, 1, 2, 3, 4, 5, 6, 7, 24, 32, and 72 h after the end of the intravenous infusion. Urine was collected in three 24-h fractions, beginning with the start of the intravenous infusion. The total dialysate return after each instillation was collected. Dialysate volume was recorded, and a sample was retained for determination of vancomycin concentration.
Concentrations of vancomycin in serum, peritoneal dialysate, and urine were measured in duplicate by radioimmunoassay (American Diagnostics, Newport Beach, Calif.). The minimum quantifiable vancomycin concentration was 1 mg/liter. The interassay coefficients of variation for this procedure were 9, 6.5, and 9.8% at 4, 17, and 32 mg/liter, respectively.
Data analysis. The decline in vancomycin concentration in the serum of each patient was biexponential. Therefore, the data were analyzed in terms of the following equation: C = Aea + Be-t, where C is the concentration in serum at time t, A and B are the intercepts, and cx and P are the disposition rates obtained from the first and second phases, respectively, of the plot of log vancomycin concentration in serum versus time.
Initial estimates of the parameters in the above equation were obtained by standard curve stripping procedures. Final estimates were obtained by nonlinear regression analysis with the program KINA on a Control Data digital computer (University Computing Center, University of Minnesota, Minneapolis, Minn.). All vancomycin concentrations were weighted according to their reciprocal squared concentrations during the computer fitted procedure. Since the vancomycin doses were infused over a period of 30 min, results of the computer analyses were analyzed with the appropriate equations for the biphasic decay of log concentration versus time after the termination of an intravenous infusion (19) . e-') ], where C is the serum concentration at any time t, n is the number of doses, X is the dosing interval, Xo is the maintenance dose, Xo' is the loading dose, k21 is the transfer rate constant from the peripheral to central compartment, and V1 is the volume of distribution of the central compartment.
RESULTS
The vancomycin serum concentration time profile of the four subjects is shown in Fig. 1 Tables 1 and 2 , respectively. The serum clearance of vancomycin was 6.42 + 1.10 ml/min (mean ± standard deviation). This was composed of the CLR of 0.65 ± 0.00 ml/min, CLCAPD of 1.35 ± 0.35 ml/ min, and CLNR of 4.74 ± 0.93 ml/min. The CLNR of vancomycin in these four subjects approximates the total body clearance observed in patients with end-stage renal disease maintained on hemodialysis (6) .
The peritoneal dialysis concentrations of vancomycin ranged from 1.0 to 4.9 mg/liter during the 72-h observation period (Fig. 1) Although the pharmacokinetics and peritoneal dialysis clearance of vancomycin in patients undergoing chronic intermittent peritoneal dialysis have been thoroughly investigated (2, 12, 14, 17) , only limited information is available regarding the impact of CAPD on the pharmacokinetics of vancomycin (4, 18) . After a single 1-gm intraperitoneal dose was administered to four patients, Pancorbo and Comty (18) reported that ca. 54% of the dose was absorbed into the systemic circulation and that peak serum concentrations of ca. 24 mg/liter were attained. After the peak serum concentration had been attained, the mean elimination half-life was 66.9 h, and the peritoneal dialysis clearance was 2.4 ml/min. The authors concluded that therapeutic serum levels of vancomycin can be achieved after intraperitoneal administration of 1 gm of vancomycin, allowing a 6-h equilibration period. They recommended that after this dose, 10 to 20 mg of vancomycin per liter be added to each bag of dialysate to maintain therapeutic serum levels.
Bunke et al. (4) evaluated the pharmacokinetics of vancomycin after intravenous administration (five patients) and intraperitoneal administration (six patients). The mean CLCAPD and half-life of vancomycin after intraperitoneal administration closely approximated the values previously reported by Pancorbo and Comty (18) . The mean parameters after intravenous administration closely approximated the result of this investigation. The peritoneal dialysis clearance of vancomycin was 1.4 ± 0.95 ml/min, whereas the elimination half-life was 77 ± 27 h. Bunke et al. (4) 
